This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Amicus' 'Transformative' Changes Look More Like Big Step Backward

FOLD Chart

FOLD data by YCharts

Talk about a news dump. On Wednesday night, Amicus Therapeutics (FOLD) announced 1) the loss of its biggest and most important drug development partner GlaxoSmthKline (GSK - Get Report); 2) the acquisition of Callidus Biopharma, a small, privately held orphan disease drug maker; 3) a corporate restructuring in which 14% of the company's employees were fired; 4) the resignation of its chief scientific officer; and 5) $40 million in new equity and debt financing.

Amicus CEO John Crowley heralded the changes as "transformative" and said the company was now stronger and better positioned to develop new enzyme replacement therapies for orphan diseases like Fabry and Pompe.

But Amicus shares didn't budge in Wednesday's after-hours trading session -- a sign investors weren't necessarily buying into Crowley's rosy interpretation of events. 

Investors might still be trying to figure out what tonight's "repositioning" really means. Here's one way of thinking about Amicus: If you haven't already written off Amigal, the company's lead drug for Fabry, then you should now that Glaxo bailed. And without Amigal, Amicus' pipeline reverts back to preclinical candidates for orphan diseases, which means the competitive gap between it and rivals Sanofi  (SNY - Get Report) and Biomarin Pharmaceuticals (BMRN - Get Report) has grown wider. 

Perhaps the best thing to be said about Amicus today is that with the stock down 53% in the past year and a $100 million market cap, investors haven't exactly been giving the company much credit for anything. 

You can read more about the restructuring of Amicus' Amigal agreement with Glaxo here and Amicus' acquisition of Callidus here.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BMRN $68.41 0.00%
FOLD $5.99 0.00%
GSK $40.76 0.00%
SNY $39.82 0.00%
AAPL $94.02 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs